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ABSTRACT
Aim: To compare the findings and completion rate of Pill-
Cam® SB2 and SB3.
Methods: This was a retrospective single-center study that 
included 357 consecutive small bowel capsule endoscopies 
(SBCE), 173 SB2 and 184 SB3. The data collected included 
age, gender, capsule type (PillCam® SB2 or SB3), quality of 
bowel preparation, completion of the examination, gastric 
and small bowel transit time, small bowel findings, findings 
in segments other than the small bowel and the detection of 
specific anatomical markers, such as the Z line and papilla. 
Results: The mean age of the patients was 48 years and 
66.9% were female. The two main indications were sus-
picion/staging of inflammatory bowel disease (IBD) and 
obscure gastrointestinal bleeding (OGIB) (43.7% and 40.3%, 
respectively). Endoscopic findings were reported in 76.2% 
of examinations and 53.5% were relevant findings. No 
significant differences were found between SB2 and SB3 
with regard to completion rate (93.6% vs 96.2%, p = 0.27), 
overall endoscopic findings (73.4% vs 78.8%, p = 0.23), rel-
evant findings (54.3% vs 52.7%, p = 0.76), first tertile find-
ings (43.9% vs 48.9%, p = 0.35), extra-SB findings (23.7% vs 
17.3%, p = 0.14), Z line and papilla detection rate (35.9% vs 
35.7%, p = 0.97 and 27.1% vs 32.6%, p = 0.32, respectively). 
With regard to the patient subgroups with suspicion/stag-
ing of IBD, significant differences were found in relation to 
the detection of villous edema and the 3rd tertile findings, 
thus favoring SB3 (26.3% vs 43.8%, p = 0.02 and 47.4% vs 
66.3%, p = 0.02, respectively). Mucosal atrophy was signifi-
cantly more frequently diagnosed with the PillCam® SB3 in 
patients with anemia/OGIB (0% vs 8%, p = 0.03).
Conclusions: Overall, PillCam® SB3 did not improve the 
diagnostic yield compared to SB2, although it improved 
the detection of villous atrophy and segmental edema.
Key words: Small bowel capsule endoscopy. PillCam SB2. 
PillCam SB3. Obscure gastrointestinal bleeding. Crohn’s 
disease.
INTRODUCTION
Small bowel capsule endoscopy (SBCE) is no longer an 
emerging diagnostic tool but rather part of routine clini-
cal practice, with clearly defined indications (1). It was first 
approved in 2001 and since then several technical improve-
ments have been made. PillCam® SB3 has a greater image 
resolution and adaptive frame rate technology compared 
with previous versions, which increases the frame rate from 
two frames/second to six frames/second when the capsule 
is moving faster.
Some studies found a greater diagnostic yield using SB3 
(44% vs 62%, p < 0.05) and even recommend a repeat SBCE 
using SB3 in cases when SB2 was inconclusive (2). Howev-
er, previous studies have reported that the SB2-extended 
(3) battery had a lower diagnostic yield (48.5% for SB2 vs 
35% for SB2-ex, p = 0.01) compared to SB2. Thus, suggest-
ing that not all technical improvements have provided a 
diagnostic advantage.
Bearing this in mind, this study compared the completion 
rate, findings and diagnostic yield of SB2 and SB3 consider-
ing not only the global examination but also tertile assess-
ment in order to determine whether technological upgrades 
can overcome the identified pitfalls of this diagnostic tool.
METHODS
This was a retrospective study in the Gastroenterology 
Department of a university affiliated hospital that is highly 
experienced in SBCE. All videos of 357 consecutive SBCE, 
173 SB2 and 184 SB3, which were performed between Sep-
tember 2012 and August 2015 were reviewed. 
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SBCE was performed with the PillCam® SB2 or SB3 (the 
former was substituted by the latter when it became com-
mercially available) using the standard protocol within our 
center. The protocol was as follows: a clear liquid diet the 
day before the procedure and a 12h night-fast, patients 
were given 100 mg of Simethicone 30 minutes before cap-
sule ingestion and 1h after ingestion they returned to our 
center for real time visualization. If the capsule remained 
in the stomach at this point, the patient was given 10 mg of 
oral domperidone. If the capsule remained in the stomach 
after pro kinetic administration, it was passed into the duo-
denum by upper gastrointestinal endoscopy (4,5). 
The complete video obtained during each SBCE procedure 
was reviewed by one experienced gastroenterologist (over 
150 examinations). Videos were reviewed using the Rapid® 
Software at 8-12 frames per second rate; the FICE technol-
ogy was also used when necessary (6,7). 
Data with regard to age, gender, capsule type (PillCam® SB2 or 
SB3), capsule indication, quality of bowel preparation, com-
pletion of the examination, gastric and small bowel transit 
time and the presence of findings in segments other than the 
small bowel were collected. The preparation was considered 
to be acceptable or adequate if > 50% or > 75%, respectively, 
of the mucosa was in a perfect cleansing condition (5). The 
reported findings in the small bowel were: active bleeding, 
angiectasia, varices, erosions, ulcers, stenosis, polyps/mass-
es, diverticula, villous edema and villous atrophy. Both physi-
cians were required to declare the relevance of the findings in 
the clinical setting. With regard to patients undergoing SBCE 
due to a suspicion/staging of inflammatory bowel disease, 
erosions, ulcers, stenosis and villous edema were considered 
as relevant. With regard to patients undergoing SBCE due 
to obscure gastrointestinal bleeding, active bleeding, angi-
ectasia, varices, erosions, ulcers, polyps/masses and villous 
atrophy were considered as relevant. For patients undergoing 
SBCE due to unresponsive celiac disease, villous atrophy, 
ulcers and polyps/masses were considered as relevant. For 
patients undergoing SBCE for polyposis syndrome, polyps 
or masses were considered as relevant. 
The presence/absence of findings in each tertile was also 
reported and for each examination and the detection of 
specific anatomical markers such as the Z line and papilla 
were also reported. The Lewis Score (LS) was calculated 
for patients with inflammatory lesions, who were catego-
rized into three groups according to the defined and vali-
dated cut-off: non-significant inflammation if LS < 135, mild 
inflammation if LS 135-790 and moderate to severe inflam-
mation if LS ≥ 790 (8). 
Statistical analysis was performed using SPSS v.21.0 and 
a two-tailed p value < 0.05 was considered as statistically 
significant. Categorical variables were presented as fre-
quencies and percentages and compared using the Fisher’s 
exact test or Chi-squared test as appropriate. Continuous 
variables were presented as means and standard deviations 
and compared using the Student’s t test. A subgroup anal-
ysis of patients with suspicion/staging of IBD and patients 
with OGIB was also performed.
All patients signed an informed consent form and con-
sensual contraindications for the SBCE procedure were 
respected as described elsewhere (9).
RESULTS
In this study, 357 SBCE, 173 SB2 and 184 SB3, were per-
formed. The most frequent indications were suspicion/
staging of inflammatory bowel disease (IBD) and obscure 
gastrointestinal bleeding (OGIB), (43.7% and 40.3%, respec-
tively). The mean age of the patients was 47.7 ± 19.2 years 
and 66.9% were female. The median small-bowel transit 
time (SBTT) was 276.2 ± 107.6 minutes and the overall 
completion rate was 95% (339/357). With regard to bowel 
preparation, this was considered to be adequate in 62.7%, 
acceptable in 32.8% and poor in 4.5% of cases.
Endoscopic findings were reported in 76.2% (272/357) of 
the examinations and relevant findings were present in 
53.5% (191/357) of procedures. The most frequently report-
ed finding in the small bowel (SB) were ulcers and erosions 
in 29.4% and 26.3% of patients, respectively (Fig. 1). With 
regard to tertile findings, 46.5% of patients had findings in 
the first tertile, 30.3% in the second and 42% in the third. 
Findings in gastrointestinal segments other than the SB 
were reported in 20.4% of SBCE and these were most fre-
quently in the stomach (16.8%) and less frequently in the 
esophagus and colon (0.3% and 3.4%, respectively). 
There were no significant differences with regard to age (47.5 
± 20.2 vs 47.8 ± 18.3 years, p = 0.89) and gender (females in 
65.9% vs 67.9%, p = 0.68) in patients that underwent SB2 and 
SB3 PillCam®. No significant differences were found between 
SB2 and SB3 with regard to completion rate (93.6% vs 96.2%, 
p = 0.27), overall endoscopic findings (73.4% vs 78.8%, p = 
0.23), relevant findings (54.3% vs 52.7%, p = 0.76), first, sec-
ond and third tertile findings (43.9% vs 48.9%, p = 0.35; 31.2% 
vs 29.3%, p = 0.70; 37.6% vs 46.2%, p = 0.99), extra-SB findings 
(23.7% vs 17.4%, p = 0.14) and the Z line and papilla detection 
rate (35.9% vs 35.7%, p = 0.97 and 27.2% vs 32.6%, p = 0.26, 
respectively). With regard to specific findings, SB3 detected 
a greater proportion of villous edema (15.0% vs 27.7%, p = 
0.005) but no differences were found between the two cap-
sules for the detection of other findings (Fig. 2). 
There were no significant differences in the subgroup 
analysis of patients with a suspicion/staging of IBD for 
the detection of villous edema and third tertile findings, 
thus favoring SB3 (26.3% vs 43.8%, p = 0.02 and 47.4% vs 
66.3%, p = 0.02, respectively). No differences were found 
with regard to the detection of ulcers and stenosis (46.1% vs 
55.0%, p = 0.26 and 2.6% vs 3.8%, p = 0.38, respectively) or 
the Lewis score classification (LS > 135 in 52.0% vs 63.9%, p 
= 0.15). No differences were found between the two groups 
with regard to other specific findings (Table 1).
A subgroup analysis of patients with OGIB, including both 
obscure and manifested, showed that villous atrophy was 
significantly more frequently reported with the PillCam® 
SB3 (0% vs 8%, p = 0.03) and first tertile findings were also 
significantly more frequently reported with the latest Pill-
Cam® version (43.5% vs 60.0%, p = 0.047). No differences 
were found between the two groups regarding other spe-
cific findings (Table 2).
DISCUSSION
SBCE is currently a widely accepted diagnostic tool with an 
increasingly recognized value for the study of small bowel 
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Fig. 2. Comparison of the specific findings between PillCam® SB2 and SB3.
Fig. 1. Small bowel findings.
pathology. Technological improvement of this technique is 
expected to overcome the limitations and provide an even 
better diagnostic accuracy. However, few studies have been 
published regarding the diagnostic performance of SB3 
and, to our knowledge, this is the largest series comparing 
PillCam® SB2 and SB3. 
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The technical improvement may render capsule endoscopy 
more efficient for several reasons. First, since some small 
bowel diseases may present with villi alterations such as 
edema, distortion and atrophy, a greater image resolution 
may allow an increased detection frequency. Secondly, sev-
eral studies have reported that the SBCE diagnostic yield is 
related with SBTT, with a positive correlation between the 
diagnostic yield and SBTT. Thus, suggesting that the longer 
the SBTT, the higher the diagnostic yield (10,11). In fact, one 
of the main concerns regarding the SBCE diagnostic yield 
(DY) is related with proximal small bowel lesion detection. 
This segment has a faster transit time and therefore, SBCE 
has a higher rate of missed lesions within this segment 
(12,13). Since SB3 has an adaptive frame rate according 
to capsule velocity, this limitation could theoretically be 
surpassed. Considering that the major duodenal papilla is 
present in all individuals who have not undergone surgery 
and is located in the proximal small bowel, its detection 
may be used as an indirect marker of a possible missed 
lesion in the proximal small bowel during capsule endos-
copy studies. Previous reports indicate that the papilla is 
observed in under half of SBCE procedures (14). Therefore, 
theoretically, a greater papilla detection rate could be used 
as a surrogate for a better visualization of the proximal 
small bowel. 
In our cohort, no statistically significant differences in the 
completion rate between the two capsules were found and 
both techniques had over 93% of complete examinations. 
This high completion rate is probably attributable to the 
small bowel capsule protocol applied in our center, in which 
real time view and, if needed, prokinetics are used to accel-
erate the capsule entrance into the small bowel, without 
interfering with the SBTT (4). 
It was also verified that there were no statistically signif-
icant differences in the detection of small bowel lesions 
between the two capsules with regard to global findings, 
diagnostic yield, specific findings or tertile findings. These 
results are in contrast to the previously reported findings 
by Dunn et al. (2). This study found PillCam® SB3 to have 
a greater diagnostic yield than SB2 (44% vs 62%, p < 0.05) 
and even recommended a repeat capsule enteroscopy in 
cases for which SB2 capsule was equivocal. 
As described above, the papilla can be used as a surrogate 
for missed lesions within the proximal small bowel and a 
higher detection rate could imply that PillCam® SB3 with an 
adaptable frame rate provides a better visualization of the 
proximal small bowel. In the current study, even though the 
papilla was detected in a higher percentage of PillCam SB3® 
studies, this difference did not reach statistical significance 
(27.2% vs 32.6%, p = 0.26). This finding is in agreement with 
the study of Dunn et al. (2), who also found no statistically 
significant differences in the detection of the papilla using 
SB2 and SB3 (14% vs 18%, p > 0.05). Selby et al. evaluated 
the papilla detection rate using several capsules, not only 
with different frame rates but also with different fields of 
view and even different numbers of capturing heads (Pill-
Cam® SB1, SB2, ESO1 and ESO2). This study found that 
all the capsules had a suboptimal detection of the papilla 
(0%, 18%, 0% and 8%, respectively), particularly those with 
narrower fields of view (15). 
In our cohort, PillCam SB3 had a significantly higher detec-
tion rate of villous edema for all the examinations and also 
when considering only patients with a suspicion/staging of 
IBD. Villous edema is a particularly important finding in this 
setting, since its characteristics and distribution are part of 
a validated inflammation score, the Lewis score (16). This is 
available in the PillCam® capsule reading software (RAPID®). 
This score takes into account villous edema, ulcers and ste-
nosis, considering their extent and severity in the different 
SB tertiles. However, despite the higher detection rate of 
villous edema, no significant differences were found with 
Table 1. Comparison of PillCam® SB2 and SB3 in 
patients with a suspicion/staging of IBD
PillCam® SB2 
(n = 76)
PillCam® SB3 
(n = 80)
p value
Female gender (%) 68.4 71.3 0.70
Age (years ± SD) 37.1 ± 14.2 39.4 ± 14.6 0.34
Complete exam (%) 93.4 97.5 0.27
Findings (%) 71.1 81.2 0.13
Relevant findings (%) 53.9 61.2 0.36
1st tertile findings (%) 43.4 42.5 0.91
2nd tertile findings (%) 31.6 36.3 0.54
3rd tertile findings (%) 47.4 66.3 0.02
Z-line detection (%) 32.9 39.7 0.39
Papilla detection (%) 28.9 38.7 0.20
Villous edema (%) 26.3 43.8 0.02
Ulcers (%) 46.1 55.0 0.26
Stenosis (%) 2.6 3.8 0.38
SL > 135 (%) (n = 147) 52.0 63.9 0.15
Table 2. Comparison of PillCam® SB2 and SB3 in 
patients with OGIB
PillCam® SB2 
(n = 69)
PillCam® SB3 
(n = 75)
p value
Female gender (%) 60.9 65.3 0.58
Age (years ± SD) 59.7 ± 19.2 58.0 ± 17.6 0.58
Complete exam (%) 94.2 96.0 0.71
Findings (%) 78.3 81.3 0.65
Relevant findings (%) 62.3 53.3 0.28
1st tertile findings (%) 43.5 60.0 0.04
2nd tertile findings (%) 33.3 25.3 0.29
3rd tertile findings (%) 33.3 30.7 0.73
Z-line detection (%) 32.3 34.3 0.81
Papilla detection (%) 21.7 24.0 0.75
Villous atrophy (%) 0.0 8.0 0.03
Ulcers (%) 13.0 8.0 0.32
Angiectasia (%) 31.9 25.3 0.38
Polyp/tumor (%) 13.0 12.0 0.85
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regard to the Lewis score between SB2 and SB3 in this 
subset of patients. This could mean that the higher detec-
tion rate of these villi alterations does not translate into a 
greater capacity to obtain a more accurate diagnosis, nor 
to provide more precise stratification of the inflammatory 
activity. 
In addition, when considering patients undergoing SBCE 
in the setting of OGIB (both obscure and overt), a greater 
detection rate of villous atrophy was observed. Interesting-
ly, studies performed with celiac disease cases showed that 
capsule endoscopy had a greater diagnostic accuracy than 
conventional upper endoscopy for the detection of villous 
atrophy, with a moderate concordance with histology (17). 
This outperformance of capsule endoscopy over conven-
tional endoscopy is probably due to a greater image mag-
nification. Therefore, we hypothesize that, in our cohort, 
the higher villous atrophy detection precision provided by 
PillCam SB3 is related to the increased image resolution. 
In conclusion, the PillCam® SB3 did not improve the overall 
diagnostic yield nor the completion rate compared to SB2. 
Nevertheless, when particular indications were analyzed, 
significant differences with regard to the detection of villi 
alteration such as atrophy and segmental villous edema 
were found, which may be attributable to the better image 
resolution of SB3.
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